Pilot trial to assess cognitive function changes in Rett Syndrome during Trofinetide treatment
A pilot trial will evaluate cognitive function changes in Rett Syndrome patients during Trofinetide treatment using eye-tracking measures.
Asset / Drug
Drug and asset intelligence for Trofinetide with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.